Article Text

Download PDFPDF
CASE REPORT
Ziv-aflibercept: a novel option for the treatment of polypoidal choroidal vasculopathy
  1. Chetan Videkar1,
  2. Aditya Kapoor1,
  3. Jay Chhablani2,
  4. Raja Narayanan1
  1. 1Department of Retina, LV Prasad Eye Institute, Hyderabad, Telangana, India
  2. 2LV Prasad Eye Institute, Hyderabad, Telangana, India
  1. Correspondence to Dr Raja Narayanan, narayanan{at}lvpei.org

Summary

Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy usually treated using photodynamic therapy (PDT) and antivascular endothelial growth factor agents. However, these cases may sometimes be refractory to both PDT and ranibizumab or bevacizumab, and may have persistent intra-retinal fluid. Recently, studies have reported that aflibercept may be effective in such resistant cases. However, high cost and limited availability has restricted its use to only a few countries. Ziv-aflibercept (Zaltrap), a systemic analogue of aflibercept, has been tried recently and it has been effective in macular oedema. We report a case of PCV resistant to PDT and ranibizumab, which responded well to intravitreal ziv-aflibercept.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.